- Home
- CURR vs CNTX Comparison
CURR vs CNTX Comparison
Compare CURR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- CNTX
- Stock Information
- Founded
- CURR 2013
- CNTX 2015
- Country
- CURR Singapore
- CNTX United States
- Employees
- CURR N/A
- CNTX 9
- Industry
- CURR Business Services
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- CNTX Health Care
- Exchange
- CURR Nasdaq
- CNTX Nasdaq
- Market Cap
- CURR 74.0M
- CNTX 78.0M
- IPO Year
- CURR N/A
- CNTX 2021
- Fundamental
- Price
- CURR $1.19
- CNTX $0.78
- Analyst Decision
- CURR Strong Buy
- CNTX Strong Buy
- Analyst Count
- CURR 1
- CNTX 6
- Target Price
- CURR $3.50
- CNTX $6.50
- AVG Volume (30 Days)
- CURR 77.5K
- CNTX 94.4K
- Earning Date
- CURR 05-19-2025
- CNTX 05-07-2025
- Dividend Yield
- CURR N/A
- CNTX N/A
- EPS Growth
- CURR N/A
- CNTX N/A
- EPS
- CURR N/A
- CNTX N/A
- Revenue
- CURR $46,435,412.00
- CNTX N/A
- Revenue This Year
- CURR N/A
- CNTX N/A
- Revenue Next Year
- CURR $17.98
- CNTX N/A
- P/E Ratio
- CURR N/A
- CNTX N/A
- Revenue Growth
- CURR N/A
- CNTX N/A
- 52 Week Low
- CURR $1.19
- CNTX $0.55
- 52 Week High
- CURR $7.08
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- CNTX 45.08
- Support Level
- CURR N/A
- CNTX $0.74
- Resistance Level
- CURR N/A
- CNTX $0.85
- Average True Range (ATR)
- CURR 0.00
- CNTX 0.09
- MACD
- CURR 0.00
- CNTX -0.02
- Stochastic Oscillator
- CURR 0.00
- CNTX 13.67
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.